<DOC>
	<DOCNO>NCT00549692</DOCNO>
	<brief_summary>The purpose study compare omega-3 fatty acid placebo efficacy retardation increase serum creatinine ( SCr ) IgA Nephropathy</brief_summary>
	<brief_title>Efficacy Safety Omega-3 Fatty Acids ( Omacor® ) Treatment Immunoglobulin A Nephropathy</brief_title>
	<detailed_description>In current clinical study , attempt make assess safety efficacy omega-3 fatty acid compare omega-3 fatty acid placebo Korean patient IgA nephropathy .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<criteria>Patient sex age 18 Biopsyproven IgA nephropathy Baseline serum creatinine ≥ 1.2mg/dl ( Female ) , ≥ 1.4mg/dl ( Male ) Able give write informed consent Hypertension SBP &gt; 160mmHg and/or DBP &gt; 100mmHg Subject , investigator 's opinion , systemic disease would contraindicate participation study Use omega3 fatty acid analog supplement Pregnancy breast feeding time entry unwillingness comply measure contraception Current recent ( within 30 day ) exposure investigational drug Subject hypersensitivity agent previous illness Low platelet ( &lt; 100,000/㎕ ) subject high risk bleeding Use corticosteroid treatment period le 3 month prior screen Use anticoagulant treatment period within 1 month 6 half life prior screen Subject investigator 's opinion , would confront difficulty</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>